Gilead Takes Another Big Swing at Expanding Beyond HIV
Gilead Sciences has earmarked roughly $11 billion this year for three strategic acquisitions aimed at strengthening its cancer and immunology pipelines. The moves signal a decisive pivot away from its historic reliance on HIV therapeutics toward broader biotech markets. The targeted companies bring late‑stage assets in oncology, checkpoint inhibition, and cellular therapy, expanding Gilead’s product portfolio. Executives expect the deals to generate multi‑billion‑dollar revenue streams within the next five years.
New Gene Therapy May Help Protect the Hearts of Patients with Friedreich's Ataxia
Lexeo Therapeutics reported early-phase results for its investigational gene therapy AAVrh.10hFXN (LX2006) in Friedreich’s ataxia–associated cardiomyopathy. In a phase 1 trial of 17 adults, a single intravenous infusion was well tolerated and produced signals of cardiac improvement, while neurological scores remained...
Wildflower Once Used to Treat Wounds and Sore Throats Shows Promise in Fighting Dangerous Superbugs
Researchers at Irish universities have demonstrated that extracts from the wildflower tormentil (Potentilla erecta) possess strong antimicrobial activity against multidrug‑resistant bacteria, including strains that cause pneumonia and urinary‑tract infections. The study identified ellagic acid and agrimoniin as the key compounds...
Pemivibart Shows Safety, Prevents COVID-19 in CLL Subset in Phase 3 CANOPY Trial
A phase 3 CANOPY subset analysis evaluated pemivibart, a recombinant IgG1 monoclonal antibody, for pre‑exposure COVID‑19 prophylaxis in patients with chronic lymphocytic leukemia (CLL). Among 29 CLL participants, none developed symptomatic SARS‑CoV‑2 infection over a 180‑day follow‑up, and the safety profile...
Post-HSCT Gilteritinib May Improve Outcomes in R/R FLT3-Mutated AML
A systematic review of eight studies suggests that post‑transplant gilteritinib maintenance may markedly improve survival for patients with relapsed or refractory FLT3‑mutated acute myeloid leukemia. One‑year overall survival rates ranged from 72.3% to 100%, while two‑year overall survival hovered around...
Sidewinder Therapeutics Raises $137 Million to Advance Bispecific ADCs
Sidewinder Therapeutics announced a $137 million Series B round, surpassing expectations and bringing its total capital to $162 million. The round was led by Frazier Life Sciences and Novartis Venture Fund, with participation from OrbiMed, DCVC Bio, Goldman Sachs, and others. The funding...
A New Way To Target Metastatic Cancer
Researchers have unveiled a protein‑based delivery platform that homes to lymph nodes and releases an immune‑activating antibody only in the presence of metastatic cancer. The two‑step system first accumulates in nodes after bloodstream injection, then opens in the tumor’s chemical...
STAT+: Pharmalittle: We’re Reading About FDA Seeking New Powers over DTC Ads, an EU Pledge to Fight AMR, and More
Activist hedge fund Shah Capital, Novavax’s second‑largest shareholder with a 9% stake, announced it will vote against the company’s board nominees and executive compensation at the upcoming annual meeting. The fund is pressing the vaccine maker to accelerate cost‑cutting, launch...
It’s Time to Put Guardrails on GLP-1 Compounding
The article warns that the rapid rise of compounded GLP‑1 drugs—spurred by a shortage of FDA‑approved semaglutide and tirzepatide—has created a largely unregulated market fraught with safety risks. The FDA recorded 1,150 adverse‑event reports, including hospitalizations and deaths, linked to...
Researchers Develop Graphene Nanodrum and AI Platform for Rapid Single-Cell Bacterial ID and Antibiotic Testing
Researchers at TU Delft, its spin‑off SoundCell, and Reinier Haga MDC have created a graphene‑based nanodrum platform that reads the nanomotion of individual bacteria and feeds the data to AI models for rapid identification and antibiotic susceptibility testing. The label‑free...
Extracellular Vesicles: A Growing Pipeline Still Searching for Validation
Extracellular vesicles (EVs), once hailed as natural delivery vehicles, have generated a sizable pipeline but no approved therapeutics yet. More than 90 clinical studies are evaluating both native MSC‑derived vesicles and engineered platforms for regeneration, gene editing, and vaccines. Companies...
SLAS Announces the Cohort for Innovation AveNEW at SLAS Europe 2026
SLAS announced the twelve startups selected for its Innovation Ave NEW program at the SLAS Europe 2026 conference in Vienna. The cohort, representing companies from seven countries, will showcase new laboratory‑automation and discovery technologies on a dedicated exhibition floor. SLAS will cover...
Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway
Insmed announced it will drop development of its lung‑disease drug Brinsupri for hidradenitis suppurativa after the Phase 2b CEDAR trial showed no efficacy, with placebo outperforming both tested doses. The study also missed secondary endpoints, prompting the company to cease the...
Asthma Exacerbations Drop with Medium-Dose ICS to Biologic Switch
A recent analysis of 2016‑2023 Optum claims data shows that asthma patients who switched from a medium‑dose inhaled corticosteroid (ICS) directly to a biologic experienced markedly larger reductions in exacerbations and systemic corticosteroid fills than those who escalated to high‑dose ICS....
Nuvalent Reports the US FDA’s NDA Submission for Neladalkib to Treat ALK-Positive NSCLC
Nuvalent has submitted a New Drug Application to the U.S. FDA for neladalkib, an ALK‑selective inhibitor intended for patients with advanced ALK‑positive non‑small cell lung cancer (NSCLC) who have progressed after prior tyrosine‑kinase inhibitor (TKI) therapy. The filing is backed...
Women Have Awaited a Revolution in Menopause. It Hasn’t Arrived.
The menopause market has surged to roughly $17 billion, driven by celebrity awareness and telehealth startups, yet scientific backing lags behind demand. Only about 6 % of private healthcare funding is allocated to women’s health, leaving many treatments unproven and clinical guidance...
Lilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma
Eli Lilly received FDA approval for its oral obesity drug Foundayo (orforglipron), sparking a direct rivalry with Novo Nordisk’s Wegovy pill, which posted a modest efficacy edge in Phase 3 trials. The drug’s convenience—no water required—could differentiate it in a crowded market. Meanwhile,...
A High Dose of Wegovy Will Cost $50 Less than Zepbound
Novo Nordisk introduced Wegovy HD, a high‑dose GLP‑1 injection priced at $399 per month, $50 less than Eli Lilly’s Zepbound at $449. The new 7.2 mg dose triples the previous 2.4 mg maximum, aiming to boost weight‑loss efficacy. Novo’s shares jumped 2.7% following...
Insmed Shelves Brinsupri in Skin Disease After Mid-Stage Flop
Insmed announced it is discontinuing development of Brinsupri for hidradenitis suppurativa (HS) after a Phase 2b trial failed to meet its primary endpoint. The drug, originally pursued for sinus inflammation, had already been shelved in that indication last year. The...
Jeito Capital Raises Record US$1.2bn to Bankroll European Biopharma’s Next Generation
Jeito Capital closed its second biopharma fund, Jeito II, at a record $1.2 bn (about €1 bn), making it the largest raise for an independent European biotech‑focused PE firm. The fund will back 15‑20 clinical‑stage companies, allocating roughly $162 m per position across obesity,...
RoosterBio and MineBio Team up to Expand MSC Solutions Access in China
RoosterBio has signed an exclusive distribution agreement with MineBio Life Sciences to bring its research‑grade and cGMP‑grade mesenchymal stem cell (MSC) and exosome bioprocessing media to China. MineBio has already secured import clearance, allowing rapid fulfillment of orders for both...
Sequencing Method Exposes Hidden Gaps in Immune Signaling by Tracking RNA and Protein Together
University of Miami researchers unveiled CIPHER‑seq, a single‑cell platform that simultaneously profiles RNA and protein within individual immune cells. The method captures cytokine transcripts and their corresponding proteins, revealing the precise timing of immune activation. Compared with conventional workflows, CIPHER‑seq...
First Patient Dosed in CatalYm’s Phase IIb Visugromab Trial
CatalYm announced the first patient has been dosed in its Phase IIb GDFATHER‑HCC‑01 trial, evaluating visugromab as a second‑line therapy for unresectable or metastatic hepatocellular carcinoma. The blinded, randomized study combines visugromab with the PD‑1 inhibitor nivolumab and the tyrosine‑kinase inhibitor...
Halozyme and Vertex Sign Deal for Hypercon Technology
Halozyme Therapeutics’ Hypercon unit has inked a global exclusive licence with Vertex Pharmaceuticals to apply its Hypercon microparticle platform to up to three drug targets. Vertex will pay Halozyme an upfront $15 million plus potential milestones and royalties on any resulting...
STAT+: A Decade Ago, These Drugs Tore Apart the FDA. Today, They Might Be some Patients’ Best Hope
Exon‑skipping therapies for Duchenne muscular dystrophy, once a source of controversy at the FDA, are now delivering unexpected clinical benefits. A recent trial involving 39 patients, including 5‑year‑old Hawken Miller, showed functional improvements that have surprised leading experts. The drugs,...
Clarity Signs Manufacturing Supply Agreement for Copper-64 With Theragenics
Clarity Pharmaceuticals has signed a large‑scale manufacturing supply agreement with Theragenics to produce copper‑64 (Cu‑64) at Theragenics’ 134,000‑sq‑ft facility near Atlanta. Theragenics can generate about 100 Ci (3.7 TBq) of Cu‑64 per day per cyclotron, enough for roughly 2,000 patient doses. The...
Mint Explainer | Anthropic’s $400-Million Biotech Bet: What It Means for India’s Pharma Industry
Anthropic, the creator of the Claude AI model, has acquired stealth biotech startup Coefficient Bio for $400 million in an all‑stock transaction. Coefficient, founded by former Genentech computational drug discovery scientists, brings expertise in AI‑driven molecule design. The purchase underscores a...
European VC Jeito Gets $1.2B to Help Private Biotechs Control Their 'Destiny'
Jeito Capital, a Paris‑based venture firm, closed its second fund at $1.2 billion (over €1 billion, roughly $1.08 billion). The capital will be deployed to a dozen or so European drug‑development startups seeking to advance pre‑clinical and early‑stage clinical programs. By providing sizable,...
As CGT Manufacturing Scales Up, Automation and Collaboration Become Essential
Cell and gene therapy manufacturing faces a scalability crunch as single batches cost over $500,000 and skilled labor shortages drive high turnover. Companies are turning to robotics, AI, and digital dashboards to automate processes, cut contamination risk, and harness real‑time...
Siemens Healthineers Partnership Seeks to Boost Supply of Novel PET Imaging Agent
Siemens Healthineers has signed a clinical supply agreement with Australian biotech Radiopharm Theranostics to manufacture and distribute the novel PET imaging agent RAD101 in the United States. The fluorine‑18‑labeled small molecule targets suspected recurrent brain cancer that has metastasized and...
United States: President Trump Tariffs on Patented Pharmaceuticals Under Section 232
On April 2, 2026 President Trump issued a proclamation imposing a 100% ad valorem tariff on most imported patented pharmaceuticals and related active ingredients, effective July 31 for some firms and September 29 for others. The decree creates tiered rates,...
Global Drug Makers Face Pricing Pressure as China Targets Affordable Healthcare
Global drug makers are confronting intensified pricing pressure in China as Beijing expands its volume‑based procurement scheme and pushes affordable healthcare through deep discounts. While innovative therapies listed on the national reimbursement drug list (NRDL) gain market volume, mature off‑patent...
Telehealth Abortion Will Remain Available for Now, After a Federal Judge's Ruling
A federal judge in Louisiana granted a stay on a lawsuit challenging the FDA's 2023 rule that permits telehealth prescribing of the abortion pill mifepristone. The decision keeps medication abortions available nationwide while the agency completes a safety review, which...
Engineered Immunosuppressive Dendritic Cells Protect Against Cardiac Remodelling
Researchers engineered fibroblast‑activation‑protein (FAP)‑targeted immunosuppressive dendritic cells (iCDCs) that co‑express CTLA4‑Ig, PD‑L1 and IL‑10. In mouse myocardial infarction, ischemia‑reperfusion and pressure‑overload models, a single iCDC infusion markedly improved ejection fraction, reduced ventricular dilation and fibrosis, and extended survival. The therapy...
Subjective and Neurocognitive Profiling of Clinical Doses of 3,4-Methylenedioxymethamphetamine (MDMA) in Healthy Volunteers: Implications for Therapeutic Use
A recent clinical study administered therapeutic doses of MDMA (75‑125 mg) to healthy volunteers and measured both subjective experiences and neurocognitive performance. Participants reported marked increases in empathy, mood elevation, and sociability, with peak effects around 90 minutes and a return to...
What to Watch: FDA's FY 2027 Budget
The FDA’s FY 2027 budget, a $7.2 billion request, outlines several policy‑driven proposals. It seeks new statutory authority to label misleading direct‑to‑consumer drug ads as misbranded, and introduces an optional “Expedited IND” pathway to accelerate Phase 1 trials using validated pre‑clinical data. The...
Novo Nordisk's Explosive Wegovy Pill Launch Draws a New Wave of Patients Into GLP-1 Weight Loss Treatment
Novo Nordisk’s oral Wegovy pill launched in January and has already generated over 600,000 prescriptions within three months, attracting tens of thousands of new patients who previously avoided GLP‑1 injections. The drug is priced at $149‑$299 per month, markedly lower...
Court Orders FDA To Provide Update On Mifepristone Review Before Midterms
A Louisiana district judge ordered the FDA to issue an update on its Risk Evaluation and Mitigation Strategy (REMS) review for the abortion medication mifepristone within six months. The mandate arrives as the Trump administration faces pressure to clarify its...
Scientists Achieve Major Breakthrough in Safe, Reversible Male Contraception
A multinational research team announced a breakthrough in male contraception: a non‑hormonal, reversible pill that achieved 95% efficacy in Phase‑III trials. The compound, which temporarily blocks sperm maturation, proved safe across a diverse cohort with no reported hormonal side effects....
Trends in Manufacturer Coupons for Biologics: Decline in Use Despite Higher Per-Claim Value
Manufacturer-sponsored coupons for biologics have declined from 18.0% of patients in 2017 to 13.9% in 2024, even as the median coupon amount per claim rose from $60 to $90. The drop is most pronounced for obesity and diabetes therapies, while...
Long-Term Cardiac Amyloidosis Survival Benefits Seen in Extension Acoramidis Trial
The open‑label extension of the ATTRibute‑CM trial demonstrated that the transthyretin stabilizer acoramidis (Attruby) delivers sustained survival benefits out to 54 months in patients with cardiac amyloidosis. Participants who began acoramidis early and remained on therapy showed markedly lower all‑cause...
Insmed Discontinues Development of Skin Condition Drug After Mid-Stage Study Miss
Insmed announced it will discontinue development of brensocatib, its investigational therapy for hidradenitis suppurativa, after the drug failed to meet the primary efficacy endpoint in a mid‑stage trial. The study aimed to reduce painful nodules in patients with the chronic...
FDA Approves First Generic Dapagliflozin to Reduce HF Hospitalization Risk in Type 2 Diabetes
The FDA has approved the first generic dapagliflozin tablets, expanding access to the SGLT2 inhibitor that lowers heart‑failure hospitalizations in type‑2 diabetes. The generics match the branded product’s safety and efficacy profile, offering a lower‑cost alternative to Farxiga. This approval...
AlpE Combo: New Tuberculosis Treatment Breakthrough
An international research team has introduced AlpE, a novel combination of Alpibectir and ethionamide, that dramatically shortens tuberculosis therapy and boosts efficacy against drug‑resistant strains. Alpibectir, a new class of mycobacterial enzyme inhibitor, works synergistically with ethionamide to disrupt cell‑wall...
Neurocrine Grows in Endocrinology, Rare Disease with $2.9B Soleno Buyout
Neurocrine Biosciences announced a $2.9 billion cash acquisition of Soleno Therapeutics, adding the FDA‑approved Vykat XR for Prader‑Willi syndrome to its portfolio. The deal also brings together Neurocrine’s existing marketed drugs Ingrezza and Crenessity, which together generated roughly $2.8 billion in 2025 sales....
What This AI Epitope Library Means for Vaccines, Immunotherapy and Biosensors
CIC biomaGUNE, together with Multiverse Computing, has launched epiGPTope, an AI‑driven platform that designs and classifies synthetic epitopes at scale. The system can generate a library of hundreds of thousands of protein fragments and predict whether they originate from viruses...
Navigating the Frontiers of Advanced Therapeutics and Operational Excellence
In 2026 the biopharma sector is juggling rapid advances in emerging modalities—viral vectors, multispecific antibodies and nucleic‑acid therapies—with heightened operational discipline. Companies are deploying patient‑derived xenograft models, 3‑D organoids and AI‑enhanced spectral flow cytometry to de‑risk next‑gen immunotherapies. Manufacturing focus...
Did Eli Lilly Just Strike Another Gold Mine?
Eli Lilly announced a $1.5 billion acquisition of a biotech portfolio centered on orexin‑targeting therapeutics. The deal adds late‑stage candidates for insomnia, narcolepsy and metabolic disorders to Lilly’s central‑nervous‑system pipeline. Analysts estimate the combined market for orexin drugs could surpass $10 billion by...
Argentina Repeals Pharmaceutical Patent Examination Guidelines
Argentina repealed its 2012 pharmaceutical patent examination guidelines on March 18, 2026, fulfilling commitments under the US‑Argentina Reciprocal Trade and Investment Agreement to harmonize IP standards. The outdated rules had excluded patents on crystalline forms, enantiomers, formulations and other biotech inventions, limiting...
Study Suggests $35 Monthly Insulin Cap Has Increased Patient Access
A 2023 Medicare policy capped insulin co‑payments at $35 per month, and a new study shows the limit sharply reduced patients' out‑of‑pocket spending in its first year. Average insulin expenditures fell by roughly 30%, while prescription fill rates climbed, indicating...